Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib in Recurrent IDH-mutant High Grade Gliomas
NCT03561870Phase 2Completed
- Sponsor
- Hospices Civils de Lyon
- Start
- Mar 2019
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib in high-grade glioma (HGG), sponsored by Hospices Civils de Lyon. Started Mar 2019; status: completed.
02
Drugs
olaparib
03
Conditions
high-grade glioma (HGG)
Beyond the preview
Go deeper on NCT03561870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03561870.